Real-World data sought on leukemia drug ponatinib
NCT ID NCT07356960
First seen Jan 25, 2026 · Last updated May 09, 2026 · Updated 11 times
Summary
This study reviews medical records of about 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received the drug ponatinib as their first treatment in regular medical practice. Researchers want to see how many patients achieve a deep level of cancer remission (complete molecular response) after starting ponatinib. The goal is to understand how well the drug works outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.